Industry Briefs: November 19, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: November 19, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Allergan has agreed to acquire SkinMedica’s topical aesthetics skin-care business. Read More

bioMérieux and Quanterix have entered into an agreement that gives bioMérieux worldwide exclusive rights to Quanterix’s Simoa technology in clinical laboratories and for industrial applications. Read More

GVK Biosciences has received approvals from the Atomic Energy Regulatory Board and the Indian government, to carry out 3H and 14C synthesis activities. Read More

Jubilant HollisterStier has announced that its contract manufacturing and services division has secured more than $100 million in contracts with leading pharmaceutical companies for the commercial manufacturing of multiple sterile parenteral products. Read More

Pacific BioLabs has acquired Bay Bioanalytical Laboratory, thus adding analytical and bioanalytical chemistry to Pacific BioLabs’ existing in vivo preclinical and microbiological testing services. Read More

Recipharm and Vetcare have entered into an agreement for the development and manufacture of a parenteral veterinary product. Read More

Sensient Pharmaceutical has extended its proprietary line of Microfine natural colors to provide a complete natural color coating system ideal for the nutraceutical market. Read More

Synerlab and AXA Private Equity have announced the acquisitions of Lyofal and IDD-TECH Orleans. Read More

People News

Onyx Scientific has appointed Dan Brisard business development director. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here